MedTrace Logo

Twenty-year Follow-up of the Inter99 Cohort

NCT05166447 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2024-02-28

No results posted yet for this study

Summary

Being born small increases your risk of developing Type 2 diabetes (T2D) with age. Furthermore, data even suggest that some of the diseases ("complications") in the eyes, kidneys, nerves, liver, blood vessels and heart often seen in T2D patients may not only be due to high blood sugar levels, but rather they to some extent are due to reduced growth in your mother´s womb. The Inter99 cohort included 6784 Danish citizens aged 30 to 60 years when established 20 years ago. Data from the Inter99 cohort showed a strong role of low birth weight (LBW) on T2D risk. The aim is now to reexamine risk of T2D and complications in all the alive 6004 elderly Inter99 participants. Importantly, today there are available techniques to perform detailed examinations for even the earliest signs of complications in both subjects with and without diabetes, and the results of this study will altogether provide important new insights into both the origin and classification of T2D and associated complications. It is hypothesized that being born with lower birth weights increases the adult risk of T2D and heart disease and associated complications in the large and smaller blood vessels.

Conditions

Sponsors & Collaborators

  • Steno Diabetes Center Copenhagen

    collaborator OTHER

  • The Novo Nordisk Foundation Center for Basic Metabolic Research

    collaborator OTHER

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Bispebjerg Hospital

    lead OTHER

Principal Investigators

  • Allan A Vaag, D.M.Sc/D.Sc · Steno Diabetes Center Copenhagen, The Capital Region of Denmark

  • Allan Linneberg, PhD · Center for Clinical Research and Prevention, The Capital Region of Denmark

Eligibility

Min Age
50 Years
Max Age
82 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-13
Primary Completion
2024-09-01
Completion
2028-12-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05166447 on ClinicalTrials.gov